Event guide: 5th Novel Conjugates Summit 2026

	Antibodies
	The latest antibodies news from News Medical

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4th Novel Conjugates Summit gives you an insider’s perspective on what’s working, what’s next, and what’s gaining traction across the industry.

View the Event Guide

			Unlocking antibody assembly secrets with AI During this unique study, scientists sought to understand if artificial intelligence could be used to predict how the interior of antibodies are assembled in the body.

			Researchers decipher anti-MOG antibody construction, paving way for therapies MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a protein in the myelin layer that surrounds the neurons in the brain. It is believed that these antibodies contribute to the destruction of this protective layer in the brain.

	Genetic Differences Can Undermine Antibody-Based Therapies The genome differs from person to person in thousands of positions. In some cases, this means that proteins have a different building block in certain regions, rendering some antibody-based therapies ineffective, report researchers from the University of Basel, Switzerland.

	Antibody therapy clears residual multiple myeloma in early trial Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

	Remodeling the tumor microenvironment to unlock CAR-T cell potential Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

	Genetic differences can affect the effectiveness of antibody therapies The genome differs from person to person in thousands of positions. In some cases, this means that proteins have a different building block in certain regions, rendering some antibody-based therapies ineffective, report researchers from the University of Basel, Switzerland.

	Researchers develop antibody to combat HCMV, a common, overlooked virus Researchers at Texas Biologics have made an important discovery that could improve treatment of human cytomegalovirus (HCMV), a common but overlooked virus that poses serious risks to vulnerable populations, including people with compromised immune systems. According to the Centers for Disease Control and Prevention, the virus is the most infectious cause of birth defects in the United States.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026